Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus TEMARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus TEMARIL.
AZELASTINE HYDROCHLORIDE vs TEMARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine hydrochloride is a phthalazinone derivative that exerts its effect by competitively inhibiting histamine at the H1 receptor site. It also stabilizes mast cells, reducing the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This dual action provides both antihistaminic and anti-inflammatory effects.
Temaril (trimeprazine tartrate and prednisolone) combines an antipruritic phenothiazine antihistamine with a corticosteroid. Trimeprazine blocks histamine H1 receptors, reducing pruritus and allergic reactions. Prednisolone suppresses inflammation via glucocorticoid receptor activation, inhibiting phospholipase A2 and cytokine production.
1 spray (137 mcg) per nostril twice daily; ophthalmic: 1 drop in affected eye(s) twice daily.
2.5 mg orally twice daily or 5 mg orally at bedtime; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 22 hours (range 20–25 hours) following oral administration, supporting twice-daily dosing. For ophthalmic and intranasal routes, systemic half-life is similar due to absorption.
Terminal elimination half-life is 9–12 hours in adults; prolonged in hepatic impairment (up to 20 hours). Given TID dosing, steady state is reached within 2 days.
Approximately 75% of the dose is excreted in feces as unchanged drug and metabolites; about 25% is excreted renally, with less than 10% as unchanged drug.
Primarily via kidneys as metabolites; unchanged drug accounts for <1%. Biliary/fecal excretion is minor. Approx. 90% recovered in urine within 24 hours.
Category C
Category C
Antihistamine
Antihistamine